Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse eve...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 17 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | algorithm review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
11/24/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=153894056&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 153894056 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 11/24/2021 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 153894056 153894056 153894056 10.1177/11795549211056261 153894056 ppf: 1 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. aug: au: Cheng, Ke Wang, Yuqing Zhou, Yuwen Xia, Ruolan Tang, Liansha Liu, Jiyan affil: Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China sug: subj: Immune Checkpoint Inhibitors Adverse Effects Immune Checkpoint Inhibitors Therapeutic Use Carcinoma, Non-Small-Cell Lung Drug Therapy Neurotoxicity Syndromes Chemically Induced Nivolumab Antibodies, Monoclonal Polyneuropathies Chemically Induced Bell Palsy Chemically Induced Brain Diseases Chemically Induced Myasthenia Gravis Chemically Induced Morbidity Prevention and Control ab: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse events (irAEs). Several ICIs, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, have been approved by the US Food and Drug Administration (FDA) to treat advanced NSCLC, accompanied by a broad spectrum of toxicity reactions. However, ICIs-associated neurological toxicities, regarding polyneuropathy, Bell palsy, encephalopathy, and myasthenia gravis, as uncommon emerging toxicities have not been well recognized, present a challenge for clinicians to improve awareness of supervision, recognition, and management before death from them. Herein, we have summarized the incidence, diagnosis, clinical manifestations, potential mechanisms, treatments, and outcomes of ICIs-related neurotoxicity and optimized the management approach for NSCLC patients. Prompt recognition and proper management are indispensable to reduce the morbidity of these patients with immune-related neurological toxicities. pubtype: Academic Journal doctype: algorithm review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|